Table 1.
Baseline characteristics of 59 HIV-infected patients and biopsy-proven tubulointerstitial nephropathies
| All Patients (n=59) | Tubulopathy (n=29, 49%) | Interstitial Nephritis (n=30, 51%) | |
|---|---|---|---|
| Median age, yr (range) | 45 (23–85) | 44 (23–85) | 45.5 (29–67) |
| Men, n (%) | 45 (76.3) | 22 (75.8) | 23 (76.7) |
| Black, n (%) | 16 (27.1) | 6 (20.7) | 10 (33.3) |
| AIDS stage, n (%) | 37 (62.7) | 20 (69) | 17 (56.7) |
| Median CD4 count, cell/µL (range) | 178.5 (1–974) | 169 (1–729) | 205 (6–974) |
| CD4 count<200/mm3, n (%) | 29 (58) | 18 (64.3) | 11 (50) |
| Detectable HIV viral load, n (%) | 27 (52.9) | 15 (55.6) | 12 (50) |
| Median, cp/ml (range) | 15.103 (94–10.106) | 8.103 (200–10.106) | 21.103 (94–39.104) |
| Opportunistic infections, n (%) | 37 (62.7) | 20 (69) | 17 (56.7) |
| Tuberculosis | 11 (29.7) | 4 (20) | 7 (41.2) |
| Atypical mycobacterial infection | 7 (18.9) | 3 (15) | 4 (23.5) |
| CMV disease | 17 (45.9) | 11 (55) | 6 (35.3) |
| Pneumocystosis | 8 (21.6) | 6 (30) | 2 (11.8) |
| Toxoplasmosis | 3 (8.1) | 3 (15) | — |
| Esophageal candidiasis | 3 (8.1) | 2 (10) | 1 (5.9) |
| Other | 7 (18.9) | 6 (30) | 1 (5.9) |
| Malignancies, n (%) | |||
| Kaposi sarcoma | 5 (8.5) | 3 (10.3) | 2 (6.7) |
| Multicentric Castleman disease | 1 (1.7) | — | 1 (3.3) |
| Lymphoma | 2 (3.4) | 1 (3.4) | 1 (3.3) |
| Coinfection, n (%) | |||
| Hepatitis B | 12 (20.3) | 7 (24.1) | 5 (16.7) |
| Hepatitis C | 8 (13.6) | 4 (13.8) | 4 (13.3) |
| Exposure to ARV therapy, n (%) | 50 (89.3) | 27 (93.1) | 23 (85.2) |
| Ritonavir | 37 (75.5) | 24 (88.9) | 13 (59.1) |
| Lamivudine | 33 (67.3) | 17 (63) | 16 (72.7) |
| Tenofovir | 29 (59.2) | 21 (77.8) | 8 (36.4) |
| Abacavir | 18 (36.7) | 9 (33.3) | 9 (40.9) |
| Lopinavir | 15 (30.6) | 7 (25.9) | 8 (36.4) |
| Zidovudine | 11 (22.4) | 6 (22.2) | 5 (22.7) |
| Atazanavir | 9 (18.4) | 7 (25.9) | 2 (9.1) |
| Indinavir | 8 (16.3) | 3 (11.1) | 5 (22.7) |
| Stavudine | 5 (10.2) | 3 (11.1) | 2 (9.1) |
| Didanosine | 5 (10.2) | 4 (14.8) | 1 (4.5) |
CMV, cytomegalovirus; ARV, antiretroviral.